Immunotherapy of HPV-associated cancer: DNA/plant-derived vaccines and new orthotopic mouse models

Cancer Immunology, Immunotherapy

Volumn 64, Issue 10, 2015, Pages 1329-1338

  Venuti, Aldo ^a   Curzio, Gianfranca ^a   Mariani, Luciano ^a   Paolini, Francesca ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cervical cancer; DNA vaccine; Head neck cancer; HPV; PIVAC 14; Plant vaccine

Indexed keywords

CANCER VACCINE; DNA VACCINE; PLANT VACCINE; UNCLASSIFIED DRUG; VACCINE; PLANT ANTIGEN;

ANIMAL MODEL; CANCER IMMUNIZATION; CANCER IMMUNOLOGY; DISEASE ASSOCIATION; DNA IMMUNIZATION; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; INTERVENTION STUDY; MOUSE; MOUSE MODEL; NEOPLASM; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TUMOR IMMUNITY; TUMOR XENOGRAFT; VIRUS CARCINOGENESIS; WART VIRUS; ANIMAL; DISEASE MODEL; FEMALE; HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOLOGY; IMMUNOTHERAPY; PAPILLOMAVIRUS INFECTIONS; PHYSIOLOGY; PLANT; PROCEDURES; RESPIRATORY TRACT NEOPLASMS; UTERINE CERVICAL NEOPLASMS;

ANIMALS; ANTIGENS, PLANT; DISEASE MODELS, ANIMAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOTHERAPY; PAPILLOMAVIRUS INFECTIONS; PLANTS; RESPIRATORY TRACT NEOPLASMS; UTERINE CERVICAL NEOPLASMS; VACCINES, DNA;

EID: 84940721014     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1734-0     Document Type: Review

References (58)

1. Venuti A, Badaracco G, Rizzo C et al (2004) Presence of HPV in head and neck tumours: high prevalence in tonsillar localization. J Exp Clin Cancer Res 23:561–566
2. Chaturvedi AK, Engels EA, Pfeiffer RM et al (2011) Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 29:4294–4301
3. Herrero R, Quint W, Hildesheim A et al (2013) Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One 8:e68329
4. Parkin DM, Bray F, Ferlay J et al (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153–156
5. Tyler M, Tumban E, Chackerian B (2014) Second-generation prophylactic HPV vaccines: successes and challenges. Expert Rev Vaccines 13:247–255
6. Steele JC, Mann CH, Rookes S et al (2005) T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia. Br J Cancer 93:248–259
7. Scott M, Nakagawa M, Moscicki AB (2001) Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol 8:209–220 Review
8. Crosbie EJ, Einstein MH, Franceschi S et al (2013) Human papillomavirus and cervical cancer. Lancet 382:889–899
9. Piersma SJ (2011) Immunosuppressive tumor microenvironment in cervical cancer patients. Cancer Microenviron 4:361–375
10. Bosch FX, Broker TR, Forman D et al (2013) Comprehensive control of human papillomavirus infections and related diseases. Vaccine 31:H1–H31
11. Vici P, Mariani L, Pizzuti L et al (2014) Immunologic treatments for precancerous lesions and uterine cervical cancer. J Exp Clin Cancer Res 33:29
12. Gurunathan S, Klinman DM, Seder RA (2000) DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 18:927–974
13. Shirota H, Klinman DM (2014) Recent progress concerning CpG DNA and its use as a vaccine adjuvant. Expert Rev Vaccines 13:299–312
14. Hemmi H, Takeuchi O, Kawai T et al (2000) A Toll-like receptor recognizes bacterial DNA. Nature 408:740–745
15. De Marco F, Hallez S, Brulet JM et al (2003) DNA vaccines against HPV-16 E7-expressing tumour cells. Anticancer Res 23:1449–1454
16. Smahel M, Síma P, Ludvíková V et al (2001) Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology 281:231–238
17. Massa S, Simeone P, Muller A et al (2008) Antitumor activity of DNA vaccines based on the human papillomavirus-16 E7 protein genetically fused to a plant virus coat protein. Hum Gene Ther 19:354–364
18. Cañizares MC, Nicholson L, Lomonossoff GP (2005) Use of viral vectors for vaccine production in plants. Immunol Cell Biol 83:263–270
19. Savelyeva N, Munday R, Spellerberg MB et al (2001) Plant viral genes in DNA idiotypic vaccines activate linked CD4+ T-cell mediated immunity against B-cell malignancies. Nat Biotechnol 19:760–764
20. Gerloni M, Xiong S, Mukerjee S et al (2000) Functional cooperation between T helper cell determinants. Proc Natl Acad Sci USA 97:13269–13274
21. Feltkamp MC, Smits HL, Vierboom MP et al (1993) Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 23:2242–2249
22. O’Brien PM, Campo MS (2003) Papillomaviruses: a correlation between immune evasion and oncogenicity? Trends Microbiol 11:300–305
23. Trimble CL, Peng S, Kos F et al (2009) A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res 15:361–367
24. Vaccine therapy with or without imiquimod in treating patients with grade 3 cervical intraepithelial neoplasia (2008) https://clinicaltrials.gov/ct2/show/NCT00788164?term
25. Zong J, Peng Q, Wang Q et al (2009) Human HSP70 and modified HPV16E7 fusion DNA vaccine induces enhanced specific CD8+ T cell responses and anti-tumor effects. Oncol Rep 22:953–961
26. Ma B, Maraj B, Tran NP et al (2012) Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs 17:469–492
27. Hartley MR, Lord JM (2004) Cytotoxic ribosome-inactivating lectins from plants. Biochim Biophys Acta 1701:1–14
28. Mathew M, Verma RS (2009) Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy. Cancer Sci 100:1359–1365 Review
29. Sikriwal D, Ghosh P, Batra JK (2008) Ribosome inactivating protein saporin induces apoptosis through mitochondrial cascade, independent of translation inhibition. Int J Biochem Cell Biol 40:2880–2888
30. Massa S, Paolini F, Spanò L et al (2011) Mutants of plant genes for developing cancer vaccines. Hum Vaccin 7:147–155
31. Radaelli A, De Giuli MorghenC, Zanotto C et al (2012) A prime/boost strategy by DNA/fowlpox recombinants expressing a mutant E7 protein for the immunotherapy of HPV-associated cancers. Virus Res 170:44–52
32. Bagarazzi ML, Yan J, Morrow MP et al (2012) Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med 4:138–155
33. Venuti A (2009) Progress and challenges in the vaccine-based treatment of head and neck cancers. J Exp Clin Cancer Res 28:69 Review
34. Chuang CM, Hoory T, Monie A et al (2009) Enhancing therapeutic HPV DNA vaccine potency through depletion of CD4+ CD25+ T regulatory cells. Vaccine 27:684–689
35. Franconi R, Venuti A (2006) HPV vaccines in plants: an appetising solution to control Infection and associated cancers. In: Campo MS (ed) Papillomavirus research from natural history to vaccines and beyond. Caister Academic Press, Norfolk, pp 357–372
36. Rybicki EP (2009) Plant-produced vaccines: promise and reality. Drug Discov Today 14:16–24
37. Franconi R, Demurtas OC, Massa S (2010) Plant-derived vaccines and other therapeutics produced in contained systems. Expert Rev Vaccines 9:877–892
38. McCormick AA (2011) Tobacco derived cancer vaccines for non-Hodgkin’s lymphoma:perspectives and progress. Hum Vaccines 7:305–312
39. Warzecha H, Mason HS, Lane C et al (2003) Oral immunogenicity of human papillomavirus-like particles expressed in potato. J Virol 77:8702–8711
40. Biemelt S, Sonnewald U, Galmbacher P et al (2003) Production of human papillomavirus type 16 virus-like particles in transgenic plants. J Virol 77:9211–9220
41. Kohl T, Hitzeroth II, Stewart D et al (2006) Plant-produced cottontail rabbit papillomavirus L1 protein protects against tumor challenge: a proof-of-concept study. Clin Vaccine Immunol 13:845–853
42. Fernández-San Millán A, Ortigosa SM, Hervás-Stubbs S et al (2008) Human papillomavirus L1 protein expressed in tobacco chloroplasts self-assembles into virus-like particles that are highly immunogenic. Plant Biotechnol J 6:427–441
43. Franconi R, Di Bonito P, Dibello F et al (2002) Plant-derived human papillomavirus 16 E7 oncoprotein induces immune response and specific tumor protection. Cancer Res 62:3654–3658
44. Franconi R, Massa S, Illiano E et al (2006) Exploiting the plant secretory pathway to improve the anticancer activity of a plant-derived HPV16 E7 vaccine. Int J Immunopathol Pharmacol 19:187–197
45. Di Bonito P, Grasso F, Mangino G et al (2009) Immunomodulatory activity of a plant extract containing human papillomavirus 16-E7 protein in human monocyte-derived dendritic cells. Int J Immunopathol Pharmacol 22:967–978
46. Musiychuk K, Stephenson N, Bi H et al (2007) A launch vector for the production of vaccine antigens in plants. Influenza Other Respir Viruses 1:19–25
47. Massa S, Franconi R, Brandi R et al (2007) Anti-cancer activity of plant-produced HPV16 E7 vaccine. Vaccine 25:3018–3021
48. Venuti A, Massa S, Mett V et al (2009) An E7-based therapeutic vaccine protects mice against HPV16 associated cancer. Vaccine 27:3395–3397
49. Buyel JF, Bautista JA, Fischer R et al (2012) Extraction, purification and characterization of the plant-produced HPV16 subunit vaccine candidate E7 GGG. J Chromatogr B Anal Technol Biomed Life Sci 880:19–26
50. Demurtas OC, Massa S, Ferrante P et al (2013) A Chlamydomonas-derived Human Papillomavirus 16 E7 vaccine induces specific tumor protection. PLoS One 8:e61473
51. Whitehead M, Ohlschlager P, Almajhdi FN et al (2014) Human papillomavirus (HPV) type 16 E7 protein bodies cause tumour regression in mice. BMC Cancer 14:367
52. Badaracco G, Venuti A (2007) Human papillomavirus therapeutic vaccines in head and neck tumors. Expert Rev Anticancer Ther 7:753–766
53. Decrausaz L, Gonçalves AR, Domingos-Pereira S et al (2011) A novel mucosal orthotopic murine model of human papillomavirus-associated genital cancers. Int J Cancer 128:2105–2113
54. Lou E, Kellman RM, Hutchison R et al (2003) Clinical and pathological features of the murine AT-84 orthotopic model of oral cancer. Oral Dis 9:305–312
55. Paolini F, Massa S, Manni I et al (2013) Immunotherapy in new pre-clinical models of HPV-associated oral cancers. Hum Vaccines Immunother 9:534–543
56. Woodland DL (2004) Jump-starting the immune system: prime-boosting comes of age. Trends Immunol 25:98–104
57. Cordeiro MN, Paolini F, Massa S et al (2015) Anti-tumor effects of genetic vaccines against HPV major oncogenes. Hum Vaccines Immunother 11:45–52
58. Vici P, Mariani L, Pizzuti L et al (2014) Emerging biological treatments for uterine cervical carcinoma. J Cancer 5:86–97